{"id":"NCT01104779","sponsor":"Forest Laboratories","briefTitle":"Safety and Efficacy of Cariprazine in Schizophrenia","officialTitle":"A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in the Acute Exacerbation of Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-04-27","primaryCompletion":"2011-12-15","completion":"2011-12-15","firstPosted":"2010-04-15","resultsPosted":"2018-11-14","lastUpdate":"2018-11-14"},"enrollment":446,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Cariprazine","otherNames":["RGH-188"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Cariprazine (3-6 mg/day)","type":"EXPERIMENTAL"},{"label":"Cariprazine (6-9 mg/day)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.","primaryOutcome":{"measure":"Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score","timeFrame":"Baseline to Week 6","effectByArm":[{"arm":"Placebo","deltaMin":-16,"sd":1.6},{"arm":"Cariprazine (3-6 mg/Day)","deltaMin":-22.8,"sd":1.6},{"arm":"Cariprazine (6-9 mg/Day)","deltaMin":-25.9,"sd":1.7}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0029"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":41,"countries":["United States","Colombia","India","South Africa"]},"refs":{"pmids":["34091867","33854317","30470662","28692485","28478771","26845266"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":161},"commonTop":["Headache","Akathisia","Insomnia","Restlessness","Constipation"]}}